Transaction DateRecipientSharesTypePriceValue
3rd December 2020Franklin M Berger6,534Exercise of derivative$4.00$26,136.00
3rd December 2020Franklin M Berger2,184Exercise of derivative$3.81$8,321.04
3rd December 2020Franklin M Berger6,773Exercise of derivative$4.67$31,629.91
3rd December 2020Franklin M Berger25,000Exercise of derivative$3.23$80,750.00
3rd December 2020Franklin M Berger1,716Exercise of derivative$4.00$6,864.00
11th June 2020Franklin M Berger100,000Open or private purchase$5.50$550,000.00
11th June 2020Talent Investments Ltd Equal1,454,545Open or private purchase$5.50$7,999,997.50
4th February 2020Christopher J. Kirk38,461Open or private purchase$2.60$99,998.60
4th February 2020Venture Investments Ltd Morningside3,800,000Open or private purchase$2.60$9,880,000.00
4th February 2020Franklin M Berger120,846Open or private purchase$2.60$314,199.60
Kezar Life Sciences
Kezar Life Sciences logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.


Kezar Life Sciences, Inc. is a clinical-stage biotechnology company. The firm specializes in the areas of protein degradation and protein secretion. Its product include KZR-616, an immunoproteasome inhibitor.


Ticker: KZR
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1645666
Employees: 40
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $17 M (15%)
Marketable Securities, Current: $140 M (121%)
Other Assets, Current: $1 M (25%)
Assets, Current: $161 M (97%)
Property, Plant and Equipment, Net: $4 M (0%)
Other Assets, Noncurrent: $282 Th (0%)
Assets: $168 M (88%)
Accounts Payable, Current: $1 M (22%)
Accrued Liabilities, Current: $3 M (0%)
Liabilities, Current: $5 M (-15%)
Liabilities: $10 M (-12%)
Common Stock, Value, Issued: $46 Th (142%)
Common Stock, Shares, Issued: $46 M (138%)
Additional Paid in Capital, Common Stock: $262 M (61%)
Retained Earnings (Accumulated Deficit): $104 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $25 Th (-87%)
Stockholders' Equity (Parent): $158 M (0%)
Liabilities and Equity: $168 M (88%)
Research and Development: $7 M (-51%)
General and Administrative Expenses: $3 M (-52%)
Operating Income/Loss: $10 M (-51%)